---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000394"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:29:54.602646+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# RxSight reports preliminary Q4 2022 revenue $16.1M, up 91% YoY; full-year $49.0M, up 117%

## Summary
- Q4 2022 revenue $16.1M (+91% YoY); 57 LDDs sold, installed base 400 LDDs as of Dec 31, 2022.
- Full-year 2022 revenue $49.0M (+117% YoY); 25,284 LALs sold.
- Preliminary cash, equivalents & short-term investments $105.8M, including $6.0M ATM net proceeds.
- Management expects continued growth in 2023; audited results targeted for early March 2023.

## SEC filing metadata
- accession: 0000950170-23-000394
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000095017023000394/0000950170-23-000394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000095017023000394/rxst-20230108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000394
- JSON: https://secwatch.observer/filing/0000950170-23-000394.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000394.txt

## Key facts
- Earnings Releases
  RxSight, Inc. reported fourth quarter and full-year 2022 results: revenue approximately $16.1 million.
  - Period: fourth quarter and full-year 2022
  - Revenue: approximately $16.1 million
  - Result: preliminary results
  source text: operational results for the fourth quarter and full-year 2022. Preliminary Unaudited Results • Preliminary unaudited fourth quarter 2022 revenue is expected to be approximately $16.1 million, representing growth of approximately 91% compared to the prior year period, driven by: o The sale of 57 Light Delivery Devices (LDDTMs), expanding the installed base to 400 LDDs
  evidence_url: https://www.sec.gov/Archives/edgar/data/1111485/000095017023000394/0000950170-23-000394-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.